PSTV Bounces After FDA Designation — But Is This a Reversal or a Dead Cat?

Why is PSTV stock moving today? Plus Therapeutics (PSTV) is commanding attention with a dramatic intraday surge of 27.44%, trading at $4.04 after dipping to a low of $3.13. This massive price action stands in stark contrast to the broader market, which is posting modest gains, and suggests a specific, high-conviction catalyst rather than a general sector rotation. The stock is currently trading at the 11.5th percentile of its 60-day range, a level often associated with capitulation, yet the sudden volume and price expansion indicate a sharp shift in sentiment from selling pressure to aggressive buying.

The primary driver behind this volatility appears to be a regulatory milestone. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's lead asset, REYOBIQ, specifically for the treatment of pediatric malignant glioma. This designation significantly expands the potential market scope and offers a period of market exclusivity, providing a tangible fundamental floor for the stock. While the company also announced the appointment of a new Chief Development Officer, the regulatory news aligns most closely with the timing and magnitude of the price gap. This is not merely a technical glitch; it is a reaction to a material event that alters the risk-reward profile of the asset in the short term.

Why is PSTV stock rising today and is the move confirmed?

While the news catalyst is clear, the technical setup suggests that the move is also heavily influenced by extreme oversold conditions that were ripe for a mechanical correction. The Relative Strength Index (RSI) on the 14-day timeframe has plummeted to 16.9, a reading that signals deeply exhausted selling pressure. Historically, such extreme readings in micro-cap biotech stocks often precede sharp mean-reversion bounces as short-sellers cover positions and value hunters step in. The volume profile supports this interpretation, with trading activity reaching 31% above the 20-day average, confirming that this is genuine demand rather than low-liquidity noise.

However, the move must be viewed with caution. The stock remains firmly embedded in a long-term downtrend, trading well below its 20-day moving average of $5.43 and its 50-day moving average of $6.27. The current rally is technically a counter-trend bounce. The chart structure shows the price breaking out of a short-term consolidation range, but the broader trend remains bearish. This creates a scenario where the stock is caught between a potential "dead cat bounce"—a temporary recovery before continuing lower—and a genuine technical reset that could lead to a more sustained rebound. The high Average True Range (ATR) of $0.54 indicates that volatility is elevated, meaning price swings will be erratic as the market digests the new information.

What is the credible trade setup and what should investors watch next?

For traders looking to capitalize on this setup, the most credible approach is a high-risk, short-term mean-reversion play targeting the 20-day moving average. The thesis relies on the stock finding a floor at current levels and attempting to test the $5.43 resistance. A practical entry zone for a long position would be between $3.85 and $4.15, provided the price holds above the immediate support of $3.13. The upside target is the 20-day MA at $5.43, with a secondary extension toward the 50-day MA at $6.27 if momentum sustains.

Crucially, the validity of this trade hinges on confirmation over the next one to two sessions. Investors should watch for sustained volume levels above the 20-day average; a drop in volume while the price rises would be a bearish divergence, suggesting the rally is fading. Furthermore, the stock must hold above the $4.00 level to maintain the bullish structure. If the price fails to break above $4.20 or if the RSI fails to climb above 30, the setup weakens significantly, and the probability of a rejection increases.

The bear case remains a serious risk. If the stock breaks below the $2.90 invalidation level with high volume, the oversold bounce thesis is invalidated, and the downtrend is likely to resume toward new lows. This would suggest that the FDA news was priced in too quickly or that the broader market sentiment is too weak to support a rebound. Additionally, if the stock closes below $3.13, it would signal that buyers have been overwhelmed by sellers, forcing a retest of the session lows.

At the end of the day, PSTV presents a classic high-beta biotech setup where a specific catalyst meets a technical extreme. The move is supported by both regulatory news and oversold mechanics, but the long-term trend remains a formidable headwind. Traders should monitor PSTV support and resistance levels closely, specifically the battle around $5.43, to determine if this is the start of a reversal or merely a pause in a bearish march. Until the price can sustain a close above the 20-day moving average, the safest stance is to treat any rally as a tactical opportunity rather than a strategic shift.